Skip to main navigation
Skip to search
Skip to main content
Sort by:
Keyphrases
Pneumoconiosis
100%
Pulmonary Fibrosis
100%
Growth Factor Inhibitors
100%
Connective Tissue Growth Factor
100%
FG-3019
42%
Mouse Model
42%
Anti-fibrosis
42%
Orphan Drug Designation
28%
Fibrosis
28%
Silica Dust
14%
Screening Method
14%
Idiopathic Pulmonary Fibrosis
14%
Specific Antibodies
14%
Bleomycin-induced Pulmonary Fibrosis
14%
Fibroblasts
14%
Therapeutic Target
14%
Aptamer
14%
Aptamer Screening
14%
AI-based Methods
14%
Duchenne muscular Dystrophy
14%
Phase III Clinical Trial
14%
Functional Domain
14%
Pulmonary Disease
14%
US FDA
14%
Occupational Exposure
14%
Proposed Work
14%
Dose Effect
14%
Pharmacology, Toxicology and Pharmaceutical Science
Lung Fibrosis
100%
Pneumoconiosis
100%
Connective Tissue Growth Factor
100%
Fibrosis
57%
Mouse Model
42%
Aptamer
28%
Orphan Drug
28%
Pamrevlumab
14%
X Chromosome Linked Muscular Dystrophic Mouse
14%
Clinical Trial
14%
Bleomycin-Induced Pulmonary Fibrosis
14%
Occupational Exposure
14%
Silicon Dioxide
14%
Fibrosing Alveolitis
14%
Lung Disease
14%